Does the media favor EW or STE?

In the previous week, Edwards Lifesciences had 18 more articles in the media than STERIS. MarketBeat recorded 22 mentions for Edwards Lifesciences and 4 mentions for STERIS. STERIS's average media sentiment score of 1.65 beat Edwards Lifesciences' score of 0.95 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edwards Lifesciences 14 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to STE or IDXX?

In the previous week, IDEXX Laboratories had 8 more articles in the media than STERIS. MarketBeat recorded 12 mentions for IDEXX Laboratories and 4 mentions for STERIS. STERIS's average media sentiment score of 1.65 beat IDEXX Laboratories' score of 1.17 indicating that STERIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive IDEXX Laboratories 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BDX or STE?

In the previous week, Becton, Dickinson and Company had 17 more articles in the media than STERIS. MarketBeat recorded 21 mentions for Becton, Dickinson and Company and 4 mentions for STERIS. STERIS's average media sentiment score of 1.65 beat Becton, Dickinson and Company's score of 1.29 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 16 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, STE or RMD?

ResMed has lower revenue, but higher earnings than STERIS. ResMed is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio STERIS $5.94B 3.48 $782.30M $7.93 26.58 ResMed $5.15B 5.26 $1.40B $10.37 17.99

Is STE or RMD more profitable?

ResMed has a net margin of 27.44% compared to STERIS's net margin of 13.18%. ResMed's return on equity of 25.35% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets STERIS 13.18% 14.15% 9.52% ResMed 27.44% 25.35% 18.69%

Does the media prefer STE or RMD?

In the previous week, ResMed had 13 more articles in the media than STERIS. MarketBeat recorded 17 mentions for ResMed and 4 mentions for STERIS. STERIS's average media sentiment score of 1.65 beat ResMed's score of 1.53 indicating that STERIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ResMed 15 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, STE or DXCM?

DexCom has lower revenue, but higher earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio STERIS $5.94B 3.48 $782.30M $7.93 26.58 DexCom $4.66B 6.20 $836.30M $2.34 32.00

Is STE or DXCM more profitable?

DexCom has a net margin of 19.31% compared to STERIS's net margin of 13.18%. DexCom's return on equity of 33.33% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets STERIS 13.18% 14.15% 9.52% DexCom 19.31% 33.33% 13.19%

Does the media refer more to STE or DXCM?

In the previous week, DexCom had 23 more articles in the media than STERIS. MarketBeat recorded 27 mentions for DexCom and 4 mentions for STERIS. STERIS's average media sentiment score of 1.65 beat DexCom's score of 1.24 indicating that STERIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DexCom 22 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

STERIS (STE) Competitors

$210.80 -1.93 (-0.91%)

Closing price 03:59 PM Eastern

Extended Trading

$211.06 +0.26 (+0.12%)

As of 04:10 PM Eastern

Compare

STE vs. EW, IDXX, BDX, RMD, and DXCM

Should you buy STERIS stock or one of its competitors? MarketBeat compares STERIS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with STERIS include Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Becton, Dickinson and Company (BDX), ResMed (RMD), and DexCom (DXCM). These companies are all part of the "health care equipment" industry.

How does STERIS compare to Edwards Lifesciences?

Edwards Lifesciences (NYSE:EW) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Edwards Lifesciences currently has a consensus price target of $95.65, indicating a potential upside of 8.29%. STERIS has a consensus price target of $278.00, indicating a potential upside of 31.88%. Given STERIS's higher probable upside, analysts clearly believe STERIS is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.79
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Edwards Lifesciences had 18 more articles in the media than STERIS. MarketBeat recorded 22 mentions for Edwards Lifesciences and 4 mentions for STERIS. STERIS's average media sentiment score of 1.65 beat Edwards Lifesciences' score of 0.95 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	14 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Edwards Lifesciences has a net margin of 17.39% compared to STERIS's net margin of 13.18%. Edwards Lifesciences' return on equity of 15.19% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.19%	11.71%
STERIS	13.18%	14.15%	9.52%

Edwards Lifesciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, STERIS has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.3% of Edwards Lifesciences shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07B	8.38	$1.07B	$1.88	46.98
STERIS	$5.94B	3.48	$782.30M	$7.93	26.58

Summary

Edwards Lifesciences beats STERIS on 11 of the 17 factors compared between the two stocks.

How does STERIS compare to IDEXX Laboratories?

STERIS (NYSE:STE) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

STERIS currently has a consensus target price of $278.00, suggesting a potential upside of 31.88%. IDEXX Laboratories has a consensus target price of $751.00, suggesting a potential upside of 32.50%. Given IDEXX Laboratories' higher probable upside, analysts clearly believe IDEXX Laboratories is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

IDEXX Laboratories has lower revenue, but higher earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.48	$782.30M	$7.93	26.58
IDEXX Laboratories	$4.30B	10.39	$1.06B	$13.58	41.74

In the previous week, IDEXX Laboratories had 8 more articles in the media than STERIS. MarketBeat recorded 12 mentions for IDEXX Laboratories and 4 mentions for STERIS. STERIS's average media sentiment score of 1.65 beat IDEXX Laboratories' score of 1.17 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
IDEXX Laboratories	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEXX Laboratories has a net margin of 24.63% compared to STERIS's net margin of 13.18%. IDEXX Laboratories' return on equity of 70.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
IDEXX Laboratories	24.63%	70.87%	32.56%

STERIS has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market.

94.7% of STERIS shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 1.1% of STERIS shares are held by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

IDEXX Laboratories beats STERIS on 11 of the 16 factors compared between the two stocks.

How does STERIS compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Becton, Dickinson and Company has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, STERIS has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

In the previous week, Becton, Dickinson and Company had 17 more articles in the media than STERIS. MarketBeat recorded 21 mentions for Becton, Dickinson and Company and 4 mentions for STERIS. STERIS's average media sentiment score of 1.65 beat Becton, Dickinson and Company's score of 1.29 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	16 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.9%. STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. Becton, Dickinson and Company pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS pays out 31.8% of its earnings in the form of a dividend. Becton, Dickinson and Company has increased its dividend for 53 consecutive years and STERIS has increased its dividend for 20 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

STERIS has a net margin of 13.18% compared to Becton, Dickinson and Company's net margin of 5.33%. Becton, Dickinson and Company's return on equity of 15.37% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	5.33%	15.37%	7.11%
STERIS	13.18%	14.15%	9.52%

Becton, Dickinson and Company presently has a consensus target price of $183.64, indicating a potential upside of 26.35%. STERIS has a consensus target price of $278.00, indicating a potential upside of 31.88%. Given STERIS's stronger consensus rating and higher possible upside, analysts plainly believe STERIS is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Becton, Dickinson and Company has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	1.83	$1.68B	$3.95	36.80
STERIS	$5.94B	3.48	$782.30M	$7.93	26.58

Summary

STERIS beats Becton, Dickinson and Company on 11 of the 19 factors compared between the two stocks.

How does STERIS compare to ResMed?

STERIS (NYSE:STE) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, ResMed had 13 more articles in the media than STERIS. MarketBeat recorded 17 mentions for ResMed and 4 mentions for STERIS. STERIS's average media sentiment score of 1.65 beat ResMed's score of 1.53 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ResMed	15 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.3%. STERIS pays out 31.8% of its earnings in the form of a dividend. ResMed pays out 23.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has raised its dividend for 20 consecutive years and ResMed has raised its dividend for 13 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and lower payout ratio.

ResMed has a net margin of 27.44% compared to STERIS's net margin of 13.18%. ResMed's return on equity of 25.35% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
ResMed	27.44%	25.35%	18.69%

STERIS presently has a consensus price target of $278.00, suggesting a potential upside of 31.88%. ResMed has a consensus price target of $286.18, suggesting a potential upside of 53.38%. Given ResMed's higher probable upside, analysts clearly believe ResMed is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73

STERIS has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, ResMed has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

94.7% of STERIS shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.7% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ResMed has lower revenue, but higher earnings than STERIS. ResMed is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.48	$782.30M	$7.93	26.58
ResMed	$5.15B	5.26	$1.40B	$10.37	17.99

Summary

ResMed beats STERIS on 12 of the 20 factors compared between the two stocks.

How does STERIS compare to DexCom?

STERIS (NYSE:STE) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

94.7% of STERIS shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, DexCom had 23 more articles in the media than STERIS. MarketBeat recorded 27 mentions for DexCom and 4 mentions for STERIS. STERIS's average media sentiment score of 1.65 beat DexCom's score of 1.24 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DexCom	22 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

STERIS has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

STERIS presently has a consensus price target of $278.00, indicating a potential upside of 31.88%. DexCom has a consensus price target of $82.42, indicating a potential upside of 10.08%. Given STERIS's higher probable upside, analysts clearly believe STERIS is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

DexCom has a net margin of 19.31% compared to STERIS's net margin of 13.18%. DexCom's return on equity of 33.33% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
DexCom	19.31%	33.33%	13.19%

DexCom has lower revenue, but higher earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.48	$782.30M	$7.93	26.58
DexCom	$4.66B	6.20	$836.30M	$2.34	32.00

Summary

DexCom beats STERIS on 12 of the 17 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STE vs. The Competition

Export

Metric	STERIS	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$20.67B	$7.10B	$6.31B	$23.24B
Dividend Yield	1.18%	1.21%	2.68%	4.09%
P/E Ratio	26.58	45.15	21.13	30.90
Price / Sales	3.48	73.85	546.66	24.79
Price / Cash	15.55	25.15	27.44	19.43
Price / Book	2.87	7.32	9.95	4.72
Net Income	$782.30M	$157.37M	$3.56B	$1.07B
7 Day Performance	-2.72%	3.48%	2.12%	1.37%
1 Month Performance	N/A	N/A	N/A	0.45%
1 Year Performance	-13.99%	2.75%	36.38%	27.94%

STERIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STE STERIS	4.7715 of 5 stars	$210.80 -0.9%	$278.00 +31.9%	-13.3%	$20.67B	$5.94B	26.58	17,787	Positive News
EW Edwards Lifesciences	3.1263 of 5 stars	$85.93 +0.2%	$95.65 +11.3%	+10.7%	$49.39B	$6.07B	45.71	16,000
IDXX IDEXX Laboratories	4.1061 of 5 stars	$559.37 flat	$751.00 +34.3%	+10.0%	$44.12B	$4.30B	41.19	11,000	Positive News
BDX Becton, Dickinson and Company	4.7769 of 5 stars	$147.76 +0.1%	$184.86 +25.1%	-14.7%	$40.68B	$21.84B	37.41	72,000	Positive News
RMD ResMed	4.8951 of 5 stars	$208.04 0.0%	$286.18 +37.6%	-22.1%	$30.31B	$5.15B	20.06	10,600	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STE) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STERIS (STE) Competitors

STE vs. EW, IDXX, BDX, RMD, and DXCM

How does STERIS compare to Edwards Lifesciences?

Summary

How does STERIS compare to IDEXX Laboratories?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Summary

How does STERIS compare to ResMed?

Summary

How does STERIS compare to DexCom?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

STERIS (STE) Competitors

STE vs. EW, IDXX, BDX, RMD, and DXCM

How does STERIS compare to Edwards Lifesciences?

Do analysts recommend EW or STE?

Does the media favor EW or STE?

Is EW or STE more profitable?

Which has more risk & volatility, EW or STE?

Do insiders & institutionals believe in EW or STE?

Which has higher valuation & earnings, EW or STE?

Summary

How does STERIS compare to IDEXX Laboratories?

Do analysts rate STE or IDXX?

Which has stronger valuation & earnings, STE or IDXX?

Does the media refer more to STE or IDXX?

Is STE or IDXX more profitable?

Which has more volatility and risk, STE or IDXX?

Do institutionals and insiders have more ownership in STE or IDXX?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Do insiders and institutionals have more ownership in BDX or STE?

Which has more risk & volatility, BDX or STE?

Does the media favor BDX or STE?

Is BDX or STE a better dividend stock?

Is BDX or STE more profitable?

Do analysts prefer BDX or STE?

Which has higher valuation & earnings, BDX or STE?

Summary

How does STERIS compare to ResMed?

Does the media prefer STE or RMD?

Is STE or RMD a better dividend stock?

Is STE or RMD more profitable?

Do analysts rate STE or RMD?

Which has more risk and volatility, STE or RMD?

Do insiders and institutionals hold more shares of STE or RMD?

Which has better earnings & valuation, STE or RMD?

Summary

How does STERIS compare to DexCom?

Do insiders & institutionals hold more shares of STE or DXCM?

Does the media refer more to STE or DXCM?

Which has more volatility and risk, STE or DXCM?

Do analysts prefer STE or DXCM?

Is STE or DXCM more profitable?

Which has stronger valuation & earnings, STE or DXCM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools